Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PARG | Q86W56 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586069 | 0.82 | NPC1 (0.35) | NPC1PTGER4DGAT1 | |
| SCHEMBL3708737 | 0.79 | PSEN1 (0.44) | NPC1 | |
| SCHEMBL3708734 | 0.79 | PSEN1 (0.44) | NPC1 | |
| SCHEMBL31140078 | 0.77 | PTGER4 (0.37) | NPC1PTGER4DGAT1 | |
| SCHEMBL3707196 | 0.77 | ENPP2 (0.37) | NPC1PTGER4 | |
| SCHEMBL3707199 | 0.77 | ENPP2 (0.37) | NPC1PTGER4 | |
| SCHEMBL3713817 | 0.76 | ENPP2 (0.34) | NPC1 | |
| SCHEMBL3713821 | 0.76 | ENPP2 (0.34) | NPC1 | |
| SCHEMBL29921380 | 0.76 | ENPP2 (0.34) | NPC1 | |
| SCHEMBL1078211 | 0.75 | NPC1 (0.38) | NPC1PTGER4DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | SLC22A12 1393/4885KLKB1 901/4885GRM4 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.